( t to improve their new-drug pipelines. ...)Patency On Two Drugs From Merck & Pfizer’s To Expire Soo,Health

t to improve their new-drug pipelines.

Any market analysts though believe that with the loss of patency, Zocor might threaten the sales of Lipitor, which is another anti cholesterol drug from Pfizer as there may now be stiff competition from the generic bands of Zocor. Reports have also shown that Lipitor was the world's top-selling drug with a estimated revenue of $12.2 billion in the 2005 sales.

Pfizer, and also certain analysts, have insisted that Lipitor is not alike with the competing products like Zocor. Officials from Pfizer have stated that they are looking to create market space by testing Lipitor that has been successful in lowering LDL or "bad" cholesterol, in combination with the experimental drug torcetrapib, which has shown to raise HDL, or "good" cholesterol. Many experts believe that if the tests are successful and the drug gets a FDA-approval then this potential combination could add billions of dollars in revenue in potential sales.

'"/>




Page: 1 2
Related medicine news :

1. Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts
2. Lean Protein Could Be Key to Obesity Drugs
3. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Emphasis to ban Drugs ads by Doctors
6. Osteoporosis Drugs: right time to take-off
7. Drugs disrupt formation of blood vessels
8. Drugs to stop burgeon of HIV
9. Misleading Advertisements for Prescription Drugs
10. Drugs For Anthrax May Interfere With Oral Contraceptives
11. Over-The-Counter Drugs May Prevent Alzheimers